相关实验视频

Updated: Jul 15, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.0K

早期的肝脏蛋白质标记揭示了大鼠高脂肪诱导肥胖的代谢变化

Abhishak C Gupta1,2, Adil Bhat2, Jaswinder S Maras2

  • 1Department of Education and Research, Artemis Hospitals, Gurugram, Haryana, India.

The British journal of nutrition
|October 27, 2023
PubMed
概括

高脂肪饮食诱导了与肥胖相关的肝蛋白显著变化. 阿基纳-1 (Arg-1) 表达增加,可能作为肥胖相关肝病进展的标志物.

关键词:
有高脂肪的饮食.矩阵辅助激光脱吸电离 飞行时间非酒精性脂肪性肝炎的疾病.两维电泳是一种二维的电泳.

更多相关视频

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH07:13

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

4.0K
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

864

相关概念视频

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...